

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Com, if Known 10/088078												
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>														
Date Submitted: March 20, 2002														
(use as many sheets as necessary)														
Sheet	1	of 2												
<table border="1"> <tr> <td><b>Application Number</b></td> <td>Unassigned</td> </tr> <tr> <td><b>Filing Date</b></td> <td>03/20/2002</td> </tr> <tr> <td><b>First Named Inventor</b></td> <td>John Alexander Edgar</td> </tr> <tr> <td><b>Group Art Unit</b></td> <td>Unassigned</td> </tr> <tr> <td><b>Examiner Name</b></td> <td>Unassigned</td> </tr> <tr> <td><b>Attorney Docket Number</b></td> <td>025217-0104</td> </tr> </table>			<b>Application Number</b>	Unassigned	<b>Filing Date</b>	03/20/2002	<b>First Named Inventor</b>	John Alexander Edgar	<b>Group Art Unit</b>	Unassigned	<b>Examiner Name</b>	Unassigned	<b>Attorney Docket Number</b>	025217-0104
<b>Application Number</b>	Unassigned													
<b>Filing Date</b>	03/20/2002													
<b>First Named Inventor</b>	John Alexander Edgar													
<b>Group Art Unit</b>	Unassigned													
<b>Examiner Name</b>	Unassigned													
<b>Attorney Docket Number</b>	025217-0104													

**U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials\* Cite No: **Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue numbers; publisher, city and/or country where published.**

Examiner Signature Jeffrey E. Russell

Date Considered September 29, 2003

**\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

<sup>1</sup> Unique citation designation number <sup>2</sup>See attached Kind of U.S. Patent Documents <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3); <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Date Submitted: March 18, 2002

(use as many sheets as necessary)

Sheet

2

of

2

## Components Known

Application Number	Unassigned 10/088,078
Filing Date	03/20/2002
First Named Inventor	John Alexander Edgar
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number: 025217-0104

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
--------------------	----------	--	----------------

- A2 VAN ASWEGEN et al., "Influence of Phomopsin and Ivalin on Steroid-Hormone Binding and Growth of MCF-7 Human Breast Cancer Cells", J. of Toxicology & Environmental Health, 1985, pp. 13-23, Vol. 16, No. 1, Hemisphere Publishing Corporation.  
 A3 LI et al., "Interaction of Phomopsin A with Porcine Brain Tubulin", Biochemical Pharmacology, 1992, pp. 219-224, Vol. 43, No. 2, Pergamon Press.  
 A4 TAKAHASHI et al., "Synthetic Study of Ustiloxin Analogs: Benzylic Oxidation of 13-Membered Cyclic Peptide by Lead Tetraacetate", Heterocycles, 1998, pp. 163-166, Vol. 47, No. 1, Inst. Of Molecular and Cellular Biosciences (IMCB), Univ. of Tokyo.

Examiner  
Signature

Jeffrey B. Russell

Date  
Considered September 29, 2003

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.